Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sirolimus ophthalmic - Santen Pharmaceutical

Next Previous
Drug Profile

Sirolimus ophthalmic - Santen Pharmaceutical

Alternative Names: DE-109; MS-R001; Opsiria; Perceiva; STN-10109; STN-1010900; STN-1010905

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MacuSight
  • Developer MacuSight; Midwest Eye Institute; Santen Pharmaceutical
  • Class 3-ring heterocyclic compounds; Alcohols; Alkenes; Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Aza compounds; Cardiovascular therapies; Cyclic ethers; Cyclohexanols; Esters; Eye disorder therapies; Ketones; Lactones; Macrocyclic compounds; Macrolides; Methyl ethers; Nootropics; Piperidines; Polyenes; Skin disorder therapies
  • Mechanism of Action Immunosuppressants; Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveitis
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Uveitis
  • Phase II Meibomian gland dysfunction
  • Discontinued Diabetic macular oedema; Dry eyes; Wet age-related macular degeneration

Most Recent Events

  • 24 Oct 2023 Santen in collaboration with Stanford University withdraws a phase II SAVE-2 trial in Uveitis in USA (Intravitreous), prior to enrolment due to sponsor decision (NCT01280669)
  • 18 Nov 2022 Santen terminates phase-III LUMINA trial in Uveitis in USA, Argentina, India and Italy due to business decision (NCT03711929; 010906IN) (EudraCT2019-003638-18).
  • 31 Aug 2022 Santen Pharmaceutical completes a phase-II clinical trials in Meibomian gland dysfunction in Japan in August 2022 (Ophthalmic) (jRCT2031210371)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top